Zoonotic & Vector-Borne Diseases

First victim of the Alaskapox Virus highlights the need for increased research.

Study offers new insight into the relationship between Zika Virus and Dengue Virus in tropical regions.

Phase 3 trial is highly effective in preventing symptomatic disease.

CDC's preventive strategies against the world's most prevalent mosquito-borne disease.

Study examines the complexity between human health and tick-borne diseases.

A new human trial aims to prevent the fatal, zoonotic-borne disease.

Valneva’s VLA1553 (Ixchiq) vaccine was shown to met its preliminary endpoint, with 98.9% of participants reaching protective levels of chikungunya virus neutralizing antibodies 1 month after vaccination.

When implemented broadly, malaria vaccines can have a significant impact on public health.

The Biden Administration addresses antimicrobial resistance with new project, company voluntarily recalls its antifungal, and a fatal case of the plague is reported in the US.

As we mark this awareness day, education and immunization has helped the United States make great strides in preventing the viral disease, but globally more work needs to be done.

The zoonotic virus has claimed 2 lives as Indian officials work to identify potential contacts and get the virus under control.

If approved, the investigational vaccine would be available to people 18 years and older.

The agency says additional time is needed to decide upon a phase 4 program.

With recent reports of this vector-borne illness in the continental United States, there is concern this might become endemic in the country again.

The vaccine is steps behind another Chikungunya vaccine candidate from Valneva, which is currently under priority review by the FDA.

Very few Lyme disease studies consider sex- and gender-based differences. Is this flawing the research?

Find out why the FDA requested additional data and what this means for dengue prevention.

6 malaria cases were confirmed in Florida and 1 in Texas, with no connection to international travel.

The federal agency has identified a total of 5 cases in Florida and Texas within the last two months.

The vaccine induced seroprotective chikungunya virus neutralizing antibodies in 98.9% of participants, regardless of age, and levels were maintained for up to 180 days.

This model proposes a risk threshold for recommending rabies postexposure prophylaxis (PEP), potentially reducing unnecessary treatments and associated costs.

The Gates Medical Research Institute (MRI) is collaborating with Atreca on an investigational therapy, MAM01, which is moving into clinic trials this year.

Among mpox patients treated with tecovirimat, there was no difference in treatment outcomes between those living with HIV and those without HIV.

The floods, heat waves, droughts, and other calamities caused by excessive greenhouse gas emissions also make us more vulnerable to ill effects of pathogens such as bacteria, viruses, plants and fungi.

The R21/Matrix-M vaccine can now be used in Ghana and could help in the prevention of a vector-borne disease that kills over 600,000 people annually.

The case and another probable case is being presented at next week’s European Congress of Clinical Microbiology & Infectious Diseases conference.

This week's hottest topics included the risks of proton pump inhibitors, rare tickborne disease, HIV vaccination, COVID-19 immunity from a common cold, and hydrocortisone for pneumonia.

The incidence rate of babesiosis in Maine, Vermont, and New Hampshire saw a dramatic increase over a multiyear period and saw an increase overall in other states where the disease is endemic.

New York City has ended their mpox outbreak after months of successful community outreach and vaccination campaigns.

This first-in-human, phase 1 vaccine trial produced a lasting immune response against Marburg virus.